STAT News reports:
Merck said Monday it will stop developing both of the current formulations of the Covid-19 vaccines the company was working on, citing inadequate immune responses to the shots.
Work will continue on at least one of the vaccines, which is being developed in partnership with the International AIDS Vaccine Initiative (IAVI), to see if using a different route of administration would improve how effective it is.
These failures are a shocking setback for one of the most storied vaccine makers, and will raise tensions around readouts expected soon from other companies, including Johnson & Johnson and the upstart NovaVax.
Read the full article.
Merck is ending development of its two Covid-19 vaccines, after they generated comparatively weak immune responses in early-stage studies https://t.co/7z8lr2kzZo
— The Wall Street Journal (@WSJ) January 25, 2021